|
1
|
Huh WW and Skapek SX: Childhood
rhabdomyosarcoma: New insight on biology and treatment. Curr Oncol
Rep. 12:402–410. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leaphart C and Rodeberg D: Pediatric
surgical oncology: Management of rhabdomyosarcoma. Surg Oncol.
16:173–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xia SJ, Pressey JG and Barr FG: Molecular
pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 1:97–104. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keller C and Guttridge DC: Mechanisms of
impaired differentiation in rhabdomyosarcoma. FEBS J.
280:4323–4334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malempati S and Hawkins DS:
Rhabdomyosarcoma: Review of the Children's Oncology Group (COG)
soft-tissue sarcoma committee experience and rationale for current
COG studies. Pediatr Blood Cancer. 59:5–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Schaftingen E, Jett MF, Hue L and Hers
HG: Control of liver 6-phosphofructokinase by fructose
2,6-bisphosphate and other effectors. Proc Natl Acad Sci USA.
78:3483–3486. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Atsumi T, Chesney J, Metz C, Leng L,
Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of
inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(iPFK-2; PFKFB3) in human cancers. Cancer Res. 62:5881–5887.
2002.PubMed/NCBI
|
|
8
|
Van Schaftingen E, Hue L and Hers HG:
Fructose 2,6-bisphosphate, the probably structure of the glucose-
and glucagon-sensitive stimulator of phosphofructokinase. Biochem
J. 192:897–901. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miralpeix M, Azcon-Bieto J, Bartrons R and
Argiles JM: The impairment of respiration by glycolysis in the
Lewis lung carcinoma. Cancer Lett. 50:173–178. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bando H, Atsumi T, Nishio T, Niwa H,
Mishima S, Shimizu C, Yoshioka N, Bucala R and Koike T:
Phosphorylation of the 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human
cancer. Clin Cancer Res. 11:5784–5792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ros S and Schulze A: Balancing glycolytic
flux: The role of 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatases in cancer metabolism. Cancer Metab. 1:82013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yalcin A, Telang S, Clem B and Chesney J:
Regulation of glucose metabolism by
6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases in cancer.
Exp Mol Pathol. 86:174–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ge X, Lyu P, Gu Y, Li L, Li J, Wang Y,
Zhang L, Fu C and Cao Z: Sonic hedgehog stimulates glycolysis and
proliferation of breast cancer cells: Modulation of PFKFB3
activation. Biochem Biophys Res Commun. 464:862–868. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z
and Tian J: PFK15, a small molecule inhibitor of PFKFB3 induces
cell cycle arrest, apoptosis and inhibits invasion in gastric
cancer. PLoS One. 11:e01637682016. View Article : Google Scholar
|
|
15
|
Hu KY, Wang de G, Liu PF, Cao YW, Wang YH,
Yang XC, Hu CX, Sun LJ and Niu HT: Targeting of MCT1 and PFKFB3
influences cell proliferation and apoptosis in bladder cancer by
altering the tumor microenvironment. Oncol Rep. 36:945–951. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Neal J, Clem A, Reynolds L, Dougherty S,
Imbert-Fernandez Y, Telang S, Chesney J and Clem BF: Inhibition of
6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and
the growth of HER2+ breast cancer. Breast Cancer Res Treat.
160:29–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feng Y and Wu L: mTOR up-regulation of
PFKFB3 is essential for acute myeloid leukemia cell survival.
Biochem Biophys Res Commun. 483:897–903. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li HM, Yang JG, Liu ZJ, Wang WM, Yu ZL,
Ren JG, Chen G, Zhang W and Jia J: Blockage of glycolysis by
targeting PFKFB3 suppresses tumor growth and metastasis in head and
neck squamous cell carcinoma. J Exp Clin Cancer Res. 36:72017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calvo MN, Bartrons R, Castaño E, Perales
J, Navarro-Sabaté A and Manzano A: PFKFB3 gene silencing decreases
glycolysis, induces cell-cycle delay and inhibits
anchorage-independent growth in HeLa cells. FEBS Lett.
580:3308–3314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lea MA, Guzman Y and Desbordes C:
Inhibition of growth by combined treatment with inhibitors of
lactate dehydrogenase and either phenformin or inhibitors of
6-phosphofructo-2-kinase/fructose-2,6-bis phosphatase 3. Anticancer
Res. 36:1479–1488. 2016.PubMed/NCBI
|
|
21
|
Clem BF, O'Neal J, Tapolsky G, Clem AL,
Imbert-Fernandez Y, Kerr DA II, Klarer AC, Redman R, Miller DM,
Trent JO, et al: Targeting 6-phosphofructo-2-kinase (PFKFB3) as a
therapeutic strategy against cancer. Mol Cancer Ther. 12:1461–1470.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scagliusi SM, Jorge V and Hugo K:
Cytopathology of callus cells infected with grapevine
leafroll-associated virus 3. Trop Plant Pathol. 27:384–388.
2002.
|
|
23
|
Liu D, Yang Y, Liu Q and Wang J:
Inhibition of autophagy by 3-MA potentiates cisplatin-induced
apoptosis in esophageal squamous cell carcinoma cells. Med Oncol.
28:105–111. 2011. View Article : Google Scholar
|
|
24
|
Lucocq JM and Hacker C: Cutting a fine
figure: On the use of thin sections in electron microscopy to
quantify autophagy. Autophagy. 9:1443–1448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muñozgámez JA, Rodríguezvargas JM,
Quilespérez R, Aguilar-Quesada R, Martín-Oliva D, de Murcia G,
Menissier de Murcia J, Almendros A, Ruiz de Almodóvar M and Oliver
FJ: PARP-1 is involved in autophagy induced by DNA damage.
Autophagy. 5:61–74. 2009. View Article : Google Scholar
|
|
27
|
Pham DL, Kim SH, Losol P, Yang EM, Shin
YS, Ye YM and Park HS: Association of autophagy related gene
polymorphisms with neutrophilic airway inflammation in adult
asthma. Korean J Intern Med. 31:375–385. 2016. View Article : Google Scholar :
|
|
28
|
Carling D: The AMP-activated protein
kinase cascade-a unifying system for energy control. Trends Biochem
Sci. 29:18–24. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Novellasdemunt L, Obach M, Millán-Ariño L,
Manzano A, Ventura F, Rosa JL, Jordan A, Navarro-Sabate A and
Bartrons R: Progestins activate
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in
breast cancer cells. Biochem J. 442:345–356. 2012. View Article : Google Scholar
|
|
30
|
Telang S, Clem BF, Klarer AC, Clem AL,
Trent JO, Bucala R and Chesney J: Small molecule inhibition of
6-phosphofructo-2-kinase suppresses t cell activation. J Transl
Med. 10:952012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim DK, Yang JS, Maiti K, Hwang JI, Kim K,
Seen D, Ahn Y, Lee C, Kang BC, Kwon HB, et al: A
gonadotropin-releasing hormone-II antagonist induces autophagy of
prostate cancer cells. Cancer Res. 69:923–931. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
D'Amours D, Desnoyers S, D'Silva I and
Poirier GG: Poly(ADP-ribosyl)ation reactions in the regulation of
nuclear functions. Biochem J. 342:249–268. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW,
Sasaki M, Klaus JA, Otsuka T, Zhang Z, Koehler RC, et al:
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad
Sci USA. 103:18308–18313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amé JC, Spenlehauer C and de Murcia G: The
PARP super-family. Bioessays. 26:882–893. 2004. View Article : Google Scholar
|
|
38
|
Kaufmann SH, Desnoyers S, Ottaviano Y,
Davidson NE and Poirier GG: Specific proteolytic cleavage of
poly(ADP-ribose) polymerase: An early marker of
chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985.
1993.PubMed/NCBI
|
|
39
|
Xi X, Zhang X, Wang B, Wang T, Wang J,
Huang H, Wang J, Jin Q and Zhao Z: The interplays between autophagy
and apoptosis induced by enterovirus 71. PLoS One. 8:e569662013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yokoyama T, Kondo Y, Bögler O and Kondo S:
The role of autophagy and apoptosis in the drug resistance of
cancer. Springer US, Drug Resistance in Cancer Cells. 53–71. 2009.
View Article : Google Scholar
|
|
41
|
Luo Z, Zang M and Guo W: AMPK as a
metabolic tumor suppressor: Control of metabolism and cell growth.
Future Oncol. 6:457–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Okoshi R, Ozaki T, Yamamoto H, Ando K,
Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H:
Activation of AMP-activated protein kinase induces p53-dependent
apoptotic cell death in response to energetic stress. J Biol Chem.
283:3979–3987. 2008. View Article : Google Scholar
|
|
43
|
Jose C, Hébert-Chatelain E, Bellance N,
Larendra A, Su M, Nouette-Gaulain K and Rossignol R: AICAR inhibits
cancer cell growth and triggers cell-type distinct effects on
OXPHOS biogenesis, oxidative stress and Akt activation. Biochim
Biophys Acta. 1807:707–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kasznicki J, Sliwinska A and Drzewoski J:
Metformin in cancer prevention and therapy. Ann Transl Med.
2:572014.PubMed/NCBI
|
|
45
|
Faubert B, Vincent EE, Poffenberger MC and
Jones RG: The AMP-activated protein kinase (AMPK) and cancer: Many
faces of a metabolic regulator. Cancer Lett. 356:165–170. 2015.
View Article : Google Scholar
|
|
46
|
Zadra G, Batista JL and Loda M: Dissecting
the dual role of AMPK in cancer: From experimental to human
studies. Mol Cancer Res. 13:1059–1072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hadad SM, Baker L, Quinlan PR, Robertson
KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG,
et al: Histological evaluation of AMPK signalling in primary breast
cancer. BMC Cancer. 9:3072009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
